Melasma (Chlosma) - Pipeline Review, H2 2016

  • ID: 3972691
  • Drug Pipelines
  • 30 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • EpiPharm AG
  • RXi Pharmaceuticals Corp
  • MORE
Melasma (Chlosma) - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Melasma (Chlosma) - Pipeline Review, H2 2016, provides an overview of the Melasma (Chlosma) (Dermatology) pipeline landscape.

Melasma is a common skin problem. The condition causes dark, discolored patches on your skin. The dark patches in melasma could be triggered by several factors, including pregnancy, birth control pills, hormone replacement therapy (HRT and progesterone), family history of melasma, race, antiseizure medications, and other medications that make the skin more prone to pigmentation after exposure to ultraviolet (UV) light.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Melasma (Chlosma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melasma (Chlosma) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 2 respectively.Melasma (Chlosma).

Melasma (Chlosma) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Melasma (Chlosma) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Melasma (Chlosma) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melasma (Chlosma) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Melasma (Chlosma) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Melasma (Chlosma) (Dermatology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Melasma (Chlosma) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Melasma (Chlosma) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • EpiPharm AG
  • RXi Pharmaceuticals Corp
  • MORE
Introduction

Melasma (Chlosma) Overview

Therapeutics Development

Pipeline Products for Melasma (Chlosma) - Overview

Melasma (Chlosma) - Therapeutics under Development by Companies

Melasma (Chlosma) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Melasma (Chlosma) - Products under Development by Companies

Melasma (Chlosma) - Companies Involved in Therapeutics Development

EpiPharm AG

Hyundai Pharmaceutical Co Ltd

RXi Pharmaceuticals Corp

Melasma (Chlosma) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

EPI-M13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPH-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tranexamic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRY-26071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRY-26077 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melasma (Chlosma) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Melasma (Chlosma), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Melasma (Chlosma) - Pipeline by EpiPharm AG, H2 2016

Melasma (Chlosma) - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2016

Melasma (Chlosma) - Pipeline by RXi Pharmaceuticals Corp, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Melasma (Chlosma) - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Melasma (Chlosma), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • EpiPharm AG
  • Hyundai Pharmaceutical Co Ltd
  • RXi Pharmaceuticals Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll